Clinical Trial: A Prospective, Multicenter Trial to Explore the Efficacy and Safety of Obinutuzumab Adds on to Standard-of-care Therapy Consisting of Mycophenolate Mofetil (MMF) and Corticosteroids (O-triple) as Initial Therapy in the Active Lupus Nephritis Patients

U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07767188) titled 'A Prospective, Multicenter Trial to Explore the Efficacy and Safety of Obinutuzumab Adds on to Standard-of-care Therapy Consisting of Mycophenolate Mofetil (MMF) and Corticosteroids (O-triple) as Initial Therapy in the Active Lupus Nephritis Patients' on Aug. 11.

Brief Summary: This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients

Study Start Date: Sept. 10

Study Type: INTERVENTIONAL

Condition: Lupus Nephritis

Intervention: DRUG: obinutuzumab (RO5072759)

Patients will receive Obinutuzumab 1000 mg at day1 (week 0) and weeks 2, 24, 26, and 52, i...